Effects of CYP2C19 Polymorphism on Metabolism and Effectiveness of Proton Pump Inhibitors: A Review of Clinical and Laboratory Studies

Introduction: Establishing the reasons for the decrease in the effectiveness of anti-Helicobacter pylori therapy and proton pump inhibitors in the treatment of acid-dependent diseases is an urgent task due to high prevalence of these disorders undermining population health. Our objective was to conduct a literature review to assess the influence of the genetic polymorphism of cytochrome P-450 CYP2C19 on the eradication rate of Helicobacter pylori and the metabolism of proton pump inhibitors, to evaluate the effectiveness of their use, and to determine possible ways of overcoming refractoriness to these drugs in the clinic. Materials and methods: We analyzed published studies found in domestic (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases. Results: We revealed a genetic polymorphism CYP2C19 of cytochrome P-450, according to which different types of drug metabolism were identified: fast, intermediate, slow, and ultrafast. The relationship of this polymorphism with biotransformation of proton pump inhibitors was then analyzed. In Russia, the predominance of fast and intermediate metabolism in individuals of the Caucasian race decreases the efficacy of acid-suppressive therapy and the Helicobacter pylori eradication rate. Correction of the daily dose and frequency of drug administration are necessary to increase the antisecretory effect of proton pump inhibitors. Discussion: The dependence of proton pump inhibitor biotransformation on the CYP2C19 polymorphism determines the differences between patients with different types of metabolism in the effectiveness of these drugs, the success of anti-Helicobacter pylori treatment, and clinical outcomes. Pharmacogenetic testing is useful for predicting the response to proton pump inhibitors, the likelihood of developing adverse events, and the possibility of personalized prescriptions in patients with acid-related diseases. Conclusion: Genetic testing of cytochrome CYP2C19 helps optimize the use of proton pump inhibitors, overcome refractoriness, and improve the quality of treatment of acid-dependent diseases and the overall Helicobacter pylori eradication rate.

1. Ivashkin VT, Mayev IV, Lapina TL, Sheptulin AA, Trukhmanov AS, Abdulkhakov RA, et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017). Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):4–21. (In Russian). doi: 10.22416/1382-4376-2017-27-4-4-21

2. Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467–78. doi: 10.1097/ MCG.0000000000000854

3. Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-624. doi: 10.1016/S0140-6736(16)32404-7

4. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol. 2017;33(6):430–438. doi: 10.1097/MOG.0000000000000392

5. Kucheryavy YuA, Andreev DN, Shaburov RI. Proton pump inhibitors in the practice of physician. Therapy. 2019;5(31):120–126. (In Russian). doi: https: //dx.doi.org/10.18565/

6. Zastrozhin MS, Skryabin VY, Torrado M, Petrovna A, Sorokin AS, Grishina EA, et al. Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics. 2020;21(2):111–123. doi: 10.2217/pgs-2019-0019

7. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447–460. doi: 10.1080/17425255.2018.1461835

8. Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: Expert review. Gastroenterology. 2021;160(5):1831–1841. doi: 10.1053/j.gastro.2020.11.059

9. Vasilevski IV. Drug – gene interaction and pharma- cotherapeutic response. Meditsinskie Novosti. 2020;(3): 5–10. (In Russian). Accessed March 3, 2021. http:// www.mednovosti.by/journal.aspx?article=8980

10. Franciosi JP, Mougey EB, Williams A, Gomez Sua- rez RA, Thomas C, Creech CL, et al. Association between CYP2С19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. Eur J Pediatr. 2018;177(1):69–77. doi: 10.1007/s00431-017-3051-4

11. Lima JJ, Thomas CD, Barbarino J, Desta Z, Driest SLV, Rouby NE, et al. Clinical Pharmacogenetics Implemen- tation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020;10.1002/cpt.2015. doi: 10.1002/cpt.2015

12. Sychev DA, Otdelenov VA, Denisenko NP, Smirnov VV. The study of the activity of isoenzymes of cytochrome P450 for the prediction of drug-drug interactions of medicines in terms of polypharmacy. Farmakogenetika i Farmakogenomika. 2016;(2):4–11. (In Russian).

13. Kitaeva EYu, Shprakh VV, Mirzaev KB, Ryzhikova KA, Shuev GN, Sozaeva ZhA, et al. Frequency of CYP2C19 and ABCB1 genes polymorphisms, associated with the change, caused by clopidogrel antiagregant among the Russians and the Buryats. Sibirskoe Meditsinskoe Obozrenie. 2018;(3(111)):43–50. (In Russian). doi: 10.20333/2500136-2018-3-43-50

14. Choi YJ, Kim N, Jang IJ, Cho J-Y, Nam RH, Park JH, et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: A randomized controlled trial in Korea. Gut Liver. 2017;11(4):504–511. doi: 10.5009/gnl16352

15. Tangamornsuksan W, Thiansupornpong P, Morasuk T, Lohitnavy O, Lohitnavy M. A pharmacokinetic model of drug–drug interaction between clopidogrel and omeprazole at CYP2C19 in humans. Annu Int Conf IEEE Eng Med Biol Soc. 2017;2017:2704–2707. doi: 10.1109/EMBC.2017.8037415

16. Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361– 366. doi: 10.1016/j.jphs.2019.03.001

17. Jing S, Zhu Y, Liu W, Yang K, Hu L, Deng D, et al. Pharmacokinetics and pharmacodynamics of esomeprazole/sodium bicarbonate immediate–release capsules in healthy Chinese volunteers: A cross-over, randomized controlled trial. Adv Ther. 2021;38(3):1660–1676. doi: 10.1007/s12325-021-01644-7

18. Ohkuma K, Iida H, Inoh Y, Kanoshima K, Ohkubo H, Nonaka T, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr. 2018;63(1):80–83. doi: 10.3164/jcbn.17-128

19. Yurenev GL, Partsvania-Vinogradova EV, Andreev DN, Dicheva DT, Maev IV. State of acid-producing function of the stomach in patients with Helicobacter pylori-associated gastroduodenal ulcer disease and no response to eradication therapy. Meditsinskiy Sovet. 2018;(6):174–179. (In Russian). doi: 10.21518/2079- 701X-2018-6-174-179

20. Kareva EN. Pharmacogenetic management concerning efficacy and safety of proton-pump inhibitors. RMJ . 2021;(4):68–73. (In Russian).

21. Zou Y, Qian X, Liu X, Song YP, Song C, Wu S, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta–analysis. Helicobacter. 2020;25(4):e12714. doi: 10.1111/hel.12714

22. Neumoina MV, Perfilova KM, Neumoina NV, Shu- tova IV, Troshina TA, Shmakova TV, et al. Resistance of Helicobacter pylori to antibacterial medications as a risk factor of infection development. Health Risk Analysis. 2020;(2):175–184. (In Russian). doi: 10.21668/ health.risk/2020.2.19.eng

23. Rabotyagova YS, Klyaritskaya IL. Investigation of cytochrom P450 2C19 genetic polymorphism and its effects on the therapy outcome in patients with gerdin the Crimean population. Vestnik Severo-Zapadnogo Gosudarstvennogo Meditsinskogo Universiteta imeni I.I. Mechnikova. 2017;9(1):96–101. (In Russian). doi: 10.17816/mechnikov20179196-101

24. Elokhina EV, Skalsky SV, Kostenko MB. Efficiency of eradication therapy at patients with the fast and slow metabolism of inhibitors of the proton pomp. Nauchnoe Obozrenie. Meditsinskie Nauki. 2015;(1):169–170. (In Russian). Accessed: February 8, 2021. https://science-medicine.ru/ru/article/view?id=792

25. Maev IV, Busarova GA, Andreev DN. [Diseases of the Esophagus.] Moscow: GEOTAR-Media Publ., 2019. Accessed March 3, 2021. https://www.rosmedlib.ru/book/ISBN9785970448748.html

26. Malfertheiner P, Megraud F, O’Morain CA, Gis- bert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection – the Maastricht V/ Florence Consensus Report. Gut. 2017;66(1):6–30. doi: 10.1136/gutjnl-2016-312288

27. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–239. doi: 10.1038/ajg.2016.563

28. Çelebi A, Aydin D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol. 2016;27(5):408–414. doi: 10.5152/tjg.2016.1551421

29. Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1–15. doi: 10.1093/ dote/dox055

30. Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton-pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716–726. doi: 10.1111/jgh.13233

31. Ivashkin VT, Maev IV, Truhmanov AS, Lapina TL, Storonova OA, Zairat’yants OV, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gasroesophageal Reflux Disease. Ross zh gastroenterol gepatol koloproktol. 2020;30(4):70–97. (In Russian). doi: 10.22416/1382-4376-2020-30-4-70-97

32. Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Terapevticheskiy Arkhiv. 2017;89(8):5–12. (In Russian). doi: 10.17116/terarkh20178985-12

33. Tamura T, Kurata M, Inoue S, Kondo T, Goto Y, Kamiya Y, et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping. Nagoya J Med Sci. 2011;73(1-2):25–31. Accessed March 3, 2021. https://www.pubfacts.com/detail/21614934

34. Lin YA, Wang H, Gu ZJ, Wang W-J, Zeng X-Y, Du Y-L, et al. Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin and levofloxacin triple therapy for eradication of Helicobacter pylori. Med Sci Monit. 2017;23:2701–2707. doi: 10.12659/msm.901514

35. Denisenko NP, Sychev DA, Sizova ZM, Rozhkov AV, Kondrashov AV. Effect of CYP2C19 genetic poly- morphisms on the efficacy of proton pump inhibitor-based triple eradication therapy in Slavic patients with peptic ulcers: a meta-analysis. Eksperimentalnaya i Klinicheskaya Gastroenterologiya. 2016;(11(135)):11–16. (In Russian).

36. Gupta K. CYP2C19 phenotype and risk of proton pump inhibitor–associated infections. Pediatrics. 2020;145(6):e20200867A. doi: 10.1542/peds.2020-0867A

37. Bernal CJ, Aka I, Carroll RJ, Coco JR, Lima JJ, Acra SA, et al. CYP2C19 phenotype and risk of proton pump inhibitor–associated infections. Pediatrics. 2019;144(6):e20190857. doi: 10.1542/peds.2019-0857

38. Sabet S, McGhee JE. New guidance on cytochrome P450 2C19 phenotype–based use of proton pump inhibitors. J Pediatr Gastroenterol Nutr. 2021;72(5):697–699. doi: 10.1097/MPG.0000000000003082

39. Schoenfeld AJ, Grady D. Adverse effects asso- ciated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–174. doi: 10.1001/jamainternmed. 2015.7927

40. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–246. doi: 10.1001/jamaintern-med.2015.7193

41. Сlooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–984. doi: 10.1111/apt.13568

42. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drum- mond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004. doi: 10.1371/journal.pone.0128004

43. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–416. doi: 10.1001/jamaneurol.2015.4791

44. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339-347. doi: 10.1007/s00198-015-3365-x

45. Galvis AA, Rangel AA, Regino WO. Personalized therapy for Helicobacter pylori: СYP2C19 genotype effect on first-line triple therapy. Helicobacter. 2019;24(3):e12574. doi: 10.1111/hel.12574

46. Bakulina NV, Maev IV, Savilova IV, Bakulin IG, Il’chishina TA, Zagorodnikova KA, et al. Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β. Terapevticheskiy Arkhiv. 2019;91(8):34–40. (In Russian). doi: 10.264 42/00403660.2019.08.000380

47. Ram MR, Teh X, Rajakumar T, Goh KL, Leow AHR, Poh BH, et al. Polymorphisms in the host SYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. J Antimicrob Chemother. 2019;74(1):11–16. doi: 10.1093/jac/dky401

48. Bikbavova GR, Akhmedov VA, Mukhamedzhanov BM. [Methods for increasing the efficacy of eradication therapy]. Russkiy Meditsinskiy Zhurnal. 2019;27(7):6–10. (In Russian).

49. Ivashkin VT, Sheptulin AA, Mayev IV, Baranskaya EK, Trukhmanov AS, Lapina TL, et al. Diagnostics and treatment of peptic ulcer: clinical guidelines of the Russian gastroenterological Association. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2016;26(6):40–54. (In Russian). doi: 10.22416/1382-4376-2016-26-6-40-54